Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1-3 prior lines of therapy, one of which contained daratumumab, were randomized to receive subcutaneous daratumumab plus carfilzomib/dexamethasone (D-Kd; <i>n</i> = 44) or carfilzomib/dexamethasone (Kd; <i>n</i> = 44). The primary endpoint was the very good partial response or better (≥VGPR) rate. At the interim futility analysis, no significant differences in ≥ VGPR rates were found between treatment groups; therefore, the null hypothesis of no treatment difference was accepted, leading to study termination. At the final analysis, 45.5% of D-Kd patients and 40.9% of Kd patients achieved ≥ VGPR (odds ratio, 1.2 [90% CI, 0.59-2.46]; <i>p</i> = 0.6757). No new safety concerns were identified. Future studies are needed to optimize daratumumab-based regimens for patients with RRMM who have prior daratumumab exposure.
Authors
- Mark‐David Levin (ORCID: https://orcid.org/0000-0003-2139-3547)
- Trine Silkjær
- Lionel Karlin (ORCID: https://orcid.org/0000-0002-1185-4488)
- Ivo Nnane
- Edvan Crusoé
- Torben Plesner (ORCID: https://orcid.org/0000-0002-2340-6068)
- Tomasz Wróbel (ORCID: https://orcid.org/0000-0002-6612-3535)
- Meletios Α. Dimopoulos (ORCID: https://orcid.org/0000-0001-8990-3254)
- Jeffrey A. Zonder (ORCID: https://orcid.org/0000-0002-1741-2795)
- Ka Lung Wu (ORCID: https://orcid.org/0000-0001-6042-978X)
- Silvia Mangiacavalli (ORCID: https://orcid.org/0000-0001-9787-3083)
- Philippe Moreau (ORCID: https://orcid.org/0000-0002-2868-7401)
- Britta Besemer
- Robin L. Carson
- Nizar Jacques Bahlis (ORCID: https://orcid.org/0000-0001-7353-7034)
- Susan Wróblewski
- Laura París (ORCID: https://orcid.org/0000-0002-8248-2343)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Maria Krevvata
- Thierry Facon
- Sosana Delimpasi (ORCID: https://orcid.org/0000-0001-7523-7510)
- Yu Jin Kim
- Vania Tietsche de Moraes Hungria (ORCID: https://orcid.org/0000-0002-4327-1957)
- Linlin Sha
- Alba Tuozzo
Institutions
- Albert Schweitzer Hospital (GA)
- Johnson & Johnson (United States) (US)
- University of Calgary (CA)
- University of Southern Denmark (DK)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Korea University (KR)
- National and Kapodistrian University of Athens (GR)
- Université de Lille (FR)
- Hotel Dieu Hospital (CA)
- Aarhus University Hospital (DK)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Wroclaw Medical University (PL)
- Complexo Hospitalar Universitário Professor Edgard Santos (BR)
- The Barbara Ann Karmanos Cancer Institute (US)
- Institute of Cancer Research (CA)
- Albert Schweitzer Ziekenhuis (NL)
- Vejle Sygehus (DK)
- Universitätsklinikum Tübingen (DE)
- Hospices Civils de Lyon (FR)
- Ospedale Papa Giovanni XXIII (IT)
- São Germano Oncologia (BR)
- Hôpital Lyon Sud (FR)
- Region of Southern Denmark (DK)
- Johnson Electric (China) (CN)
- Johnson & Johnson (Israel) (IL)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Evangelismos Hospital (GR)
- University of Tübingen (DE)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/10428194.2025.2561117
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77